Aquila Diagnostic Systems Inc. Releases Independent Trial Results For Its AccutasVET Tapeworm Fecal Test
Nov 15, 2017 — Edmonton, Alberta — Aquila Diagnostic Systems Inc. (“Aquila”) is pleased to announce results of an independent laboratory trial for its point-of-care AccutasVET DNA Tapeworm fecal test based on Aquila’s patented molecular diagnostics hydrogel technology.
Aquila Diagnostic Systems Inc. to Present at 2017 Animal Health Investment Forum in Kanas City
Aquila Diagnostic Systems Inc. is pleased to announce that it has been selected to present at the Animal Health Investment Forum, which will take place on August 29th, 2017 in Kansas City Missouri at the Kansas City Convention Center.
Aquila Diagnostic Systems Inc. Raises $1.75 Million Investment in Series A Financing
June 16, 2016 - Aquila Diagnostic Systems Inc., announces the closing of a $1.75 million Series A financing round with Benslie International Ltd.
Aquila Diagnostic Systems Inc. is a privately held Canadian company commercializing its innovative Accutas solution for a point-of-care molecular (DNA/RNA) diagnostic testing system. The patented Accutas solution provides low cost, laboratory quality diagnostics at the point-of-care, eliminating cost and inconvenience of waiting days or weeks for laboratory results to be returned and the subsequent follow-up visit or treatment. Aquila is preparing to enter large markets for the companion animal and food production sectors.
“Having something that can be out in the field, that can be affordable at a more local level and that doesn't need sophisticated laboratory technicians or laboratory equipment is going to be really invaluable.”
Dr. Maxine Whittaker, Co-Secretariat of the Asia Pacific Malaria Elimination Network (APMEN) and Professor of International and Tropical Health of the School of Public Health at the University of Queensland, Australia.